Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Roger, P.-M.
Right arrow Articles by Dellamonica, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roger, P.-M.
Right arrow Articles by Dellamonica, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 44, 129-131
© 1999 The British Society for Antimicrobial Chemotherapy

Brief report

Efficacy and safety of an intravenous induction therapy for treatment of disseminated Mycobacterium avium complex infection in AIDS patients: a pilot study

Pierre-Marie Rogera,*, Michel Carlesa, Isabelle Agussol-Foina, Liliana Pandianib, Olivia Keïta-Persea, Veronique Mondaina, Francine De Salvadora and Pierre Dellamonicaa

a Service des Maladies Infectieuses et Tropicales, Hôpital de l’Archet I, BP 79, 06202 Nice cedex 3; b Laboratoires Marcel Mérieux, BP 7322, 69357 Lyon cedex 07, France

Monotherapy with macrolides for the treatment of disseminated Mycobacterium avium complex (MAC) bacteraemia leads to drug resistance and relapse of bacteraemia. Gastrointestinal intolerance is a common reason for treatment withdrawal of multidrug regimens. We have assessed the efficacy and safety of initial parenteral therapy together with a macrolide, for disseminated MAC infection, defined as two positive blood cultures, in AIDS patients. Patients received a daily infusion of amikacin 15 mg/kg + ethambutol 20 mg/kg + ciprofloxacin 400 mg/day, for 1 month, together with a macrolide by oral route. Fifteen patients were included and 13 (86%) achieved negative culture before the end of parenteral therapy.

* Corresponding address. Services des Maladies Infectieuses, Hôpital de l’Archet 1, BP7932, 06202 Nice, France. Fax: +33-(0)4-93-96-54-54.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
C. Possoz, J. Newmark, N. Sorto, D. J. Sherratt, and M. E. Tolmasky
Sublethal Concentrations of the Aminoglycoside Amikacin Interfere with Cell Division without Affecting Chromosome Dynamics
Antimicrob. Agents Chemother., January 1, 2007; 51(1): 252 - 256.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.